Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
D WendumC Gisselbrecht

Abstract

The aims of this study were as follows: (1) to analyze clinical, histopathologic characteristics, treatment outcome, and prognostic factors of patients with follicular large-cell lymphoma (FLCL); and (2) to compare them with those of patients with diffuse large B-cell lymphoma (DLCL) treated in the same therapeutic trial. Eighty-nine FLCL patients who were histologically reviewed and who received an intensive chemotherapy regimen according to the LNH 87 protocol were analyzed and compared with 1,096 B-cell DLCL patients included in the same protocol. After intensive induction treatment, 59 patients (67%) achieved a complete remission [CR]. Estimated 5-year survival was 59%, and estimated 5-year freedom from progression (FFP) was 39%. Prognostic factors associated with shorter FFP were age greater than 60 years (P = .02), advanced clinical stage (P = .01), abnormal lactic dehydrogenase (LDH) level (P = .02), abnormal beta-2 microglobulin (P = .02), B symptoms (P = .03), bone marrow involvement (P = .04), and high expression of bcl-2 protein (P = .05). When compared with B-cell DLCL patients, FLCL patients were younger (P = .02), had a better Eastern Cooperative Oncology Group (ECOG) status (P = .05), less bulky mass (P = .04), m...Continue Reading

Citations

Aug 12, 2006·Current Oncology Reports·Andrew J Davies
Oct 11, 2007·Leukemia & Lymphoma·Christos Emmanouilides
Sep 1, 2007·Current Opinion in Oncology·Philip J Bierman
Dec 16, 2000·The American Journal of Surgical Pathology·M TakeshitaM Kikuchi
Jun 1, 2009·Expert Review of Hematology·Peter McLaughlin
May 10, 2001·International Journal of Hematology·E KondoY Morishima
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce A PetersonArlan J Gottlieb
Oct 13, 2012·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Fredrick B Hagemeister
Jul 9, 2013·The Cochrane Database of Systematic Reviews·Gilad ItchakiMical Paul
Feb 13, 2003·British Journal of Haematology·Douglas E HorsmanRandy D Gascoyne
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas RelanderRandy D Gascoyne
Oct 15, 2008·Leukemia & Lymphoma·Christian BuskeWyndham Wilson
Apr 13, 2004·Oncogene·Klaus-Michael Debatin, Peter H Krammer
Mar 12, 2021·British Journal of Haematology·Allison BarracloughEliza A Hawkes
Mar 10, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A K GantiJ O Armitage
Dec 18, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M J OvermanL E Fayad
Nov 11, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J ShustikL H Sehn

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
J R AndersonJ O Armitage
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
John F SeymourR Kurzrock
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Caroline BessonGroupe d'Etude des Lymphomes de l'Adulte Programs
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Bradford S HoppeJoachim Yahalom
© 2021 Meta ULC. All rights reserved